CSF2 and COVID-19: In line with these findings, early clinical trials of otilimab, an anti-GM-CSF (granulocyte-macrophage colony stimulating factor) monoclonal antibody, showed a reduction of all-cause mortality in older patients with severe COVID-19 (69).